Merck & Co Inc (FRA:6MK)
€ 92.9 -0.2 (-0.21%) Market Cap: 236.96 Bil Enterprise Value: 261.27 Bil PE Ratio: 21.36 PB Ratio: 5.93 GF Score: 78/100

Merck & Co Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 13, 2021 / 03:00PM GMT
Release Date Price: €61.8 (-0.45%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Well, great. Good morning, everybody, and thanks for joining us for the next session. I'm Matthew Harrison, one of the biopharma analysts here at Morgan Stanley. Very pleased to have Merck with us for the next session.

Before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.

So pleased to have Rob Davis, the CEO of Merck; and Dean Li, who runs R&D. Rob, I'm going to turn it over to you to make some opening comments, and then we can jump into Q&A.

Robert M. Davis
Merck & Co., Inc. - President, CEO & Director

Great. Well, thank you. Thanks, Matt, and thank you for having us. We can obviously get into this more in the question and answers, but I think it's important just for everyone to understand. It's an exciting time at Merck. We feel very good

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot